PDCD1 and neoplasm: These data reinforce the previous observations that KRASG12C inhibition alone does not sensitise immune-excluded tumours to anti-PD-1 and underlines the prerequisite for inhibition of both KRASG12C and SHP2 inhibition for sensitising 3LL-ΔNRAS tumours to anti-PD-1 immunotherapy24.